Latest Biotech News

Roche agreed to acquire PathAI for up to $1.05 billion to expand its digital pathology capabilities and bolster biopharma services. Under the terms, Roche will pay $750 million upfront and up to...

The FDA’s updated stance on Ebvallo centers on using the existing single-arm Allele trial with an appropriate historical control rather than demanding a new randomized study. The companies said...

Entrada’s shares plunged after initial dystrophin readouts for ENTR-601-44 in Duchenne muscular dystrophy came in below what investors expected. The trial met safety and tolerability, and...

Eli Lilly’s Mounjaro moved past Merck’s Keytruda for the first time, driven by accelerating tirzepatide sales that also benefited from strong contributions within combination demand. The...

BillionToOne told investors it expects Unity Confirm to drive further gains in its prenatal testing franchise. The company said the circulating fetal cell-based confirmatory assay is designed to...

Odyssey Therapeutics priced an initial public offering that raised $279 million after a more than year-long process, marking the second attempt to access public markets. The autoimmune disease...

DNAstack and PhenoTips announced they have integrated their informatics platforms to enable an end-to-end clinical genetics workflow that combines structured phenotype capture with genomic...

Lonza said it aims to expand its antibody-drug conjugate manufacturing footprint with a new manufacturing site coming online next year and plans to increase headcount. The company framed the move...

The FDA has agreed to reconsider its January decision to reject Ebvallo (tabelecleucel/tab-cel) for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD),...

Angelini Pharma agreed to buy Catalyst Pharmaceuticals in a $4.1 billion all-cash deal, aiming to expand its rare neurology portfolio and establish a more direct U.S. commercial presence. The...

Roche agreed to acquire PathAI for up to $1.05 billion to strengthen its digital pathology capabilities and integrate AI into diagnostics and biopharma workflows. Under the deal terms, Roche will...

Odyssey Therapeutics raised about $279 million in its initial public offering, according to company disclosures ahead of Nasdaq trading under the ticker “ODTX.” The autoimmune-focused developer...

Vyriad says it will showcase its modular G-Link CAR-T delivery platform at ASGCT, presenting new options for retargeting lentiviral vectors for in vivo delivery. The protein adapter, developed...

La Jolla Institute for Immunology (LJI) researchers reported the characterization of human monoclonal antibodies that neutralize measles virus by blocking entry through binding to the virus’s...

Two platform announcements highlighted the next wave of integrated digital health infrastructure for diagnostics and clinical workflows. First, DNAstack and PhenoTips said they integrated their...

BillionToOne reported that Q1 2026 revenue rose 84% year over year to $108.4 million, driven by growth in its prenatal testing business, and said it expects the Unity Confirm test to expand...

Tempus AI announced a private offering of $350 million in convertible senior notes, with net proceeds planned to repay $307.7 million of existing loans and interest while funding other corporate...

Bio-Rad expanded its TrailBlazer StarBright Dye Label Kits, providing a broader commercial range for conjugating antibodies to fluorophores via SpyTag and SpyCatcher chemistry. The company said...

The U.S. FDA agreed to reconsider its earlier shock rejection of Pierre Fabre Pharmaceuticals and Atara Biotherapeutics’ off-the-shelf T-cell therapy Ebvallo (tabelecleucel) after the companies...

Italy’s Angelini Pharma agreed to buy Catalyst Pharmaceuticals in an all-cash deal valuing the company at about $4.1 billion, paying $31.50 per share—an approximate 21% premium to the prior close....